Methods which increase the bioavailability of beneficial gases in the circulatory system are provided. The methods involve administering agents that changes the binding affinity of a medicinal gas such as NO, CO, H.sub.2S, N.sub.2O, SO, SO.sub.2 and O.sub.2 for IIb and/or hemoglobin based oxygen carriers (HBOCs). The change results in increased release of gases carried by Hb and HBOCs. As a result, the concentration of the gases in circulation is raised, and they are more available to exert their beneficial effects, e.g. in the treatment of disease or conditions caused by low levels of the gases. The methods are optionally used together with administration of medicinal gases and/or administration of HBOCs and/or other non-HBOC gas carriers such as PFC, and as (or in conjunction with) diagnostic methods.

Methods which increase the bioavailability of beneficial gases in the circulatory system are provided. The methods involve administering agents that changes the binding affinity of a medicinal gas such as NO, CO, H.sub.2S, N.sub.2O, SO, SO.sub.2 and O.sub.2 for IIb and/or hemoglobin based oxygen carriers (HBOCs). The change results in increased release of gases carried by Hb and HBOCs. As a result, the concentration of the gases in circulation is raised, and they are more available to exert their beneficial effects, e.g. in the treatment of disease or conditions caused by low levels of the gases. The methods are optionally used together with administration of medicinal gases and/or administration of HBOCs and/or other non-HBOC gas carriers such as PFC, and as (or in conjunction with) diagnostic methods.

Methods which increase the bioavailability of beneficial gases in the circulatory system are provided. The methods involve administering agents that changes the binding affinity of a medicinal gas such as NO, CO, H.sub.2S, N.sub.2O, SO, SO.sub.2 and O.sub.2 for IIb and/or hemoglobin based oxygen carriers (HBOCs). The change results in increased release of gases carried by Hb and HBOCs. As a result, the concentration of the gases in circulation is raised, and they are more available to exert their beneficial effects, e.g. in the treatment of disease or conditions caused by low levels of the gases. The methods are optionally used together with administration of medicinal gases and/or administration of HBOCs and/or other non-HBOC gas carriers such as PFC, and as (or in conjunction with) diagnostic methods.

Methods for cerebral cooling are described. Cooling assemblies include elongate tubular members, a reservoir containing a pressurized fluid, and a manifold connecting the reservoir and elongate tubular members. After insertion of the elongate tubular members into the patient's nostrils, a pressurized fluid is delivered onto a surface of the patient's nasal cavity through a plurality of ports in the elongate tubular members. The delivery of the fluid causes cooling by direct heat transfer through the nasopharynx and hematogenous cooling through the carotids and the Circle of Willis.

Methods for cerebral cooling are described. Cooling assemblies include elongate tubular members, a reservoir containing a pressurized fluid, and a manifold connecting the reservoir and elongate tubular members. After insertion of the elongate tubular members into the patient's nostrils, a pressurized fluid is delivered onto a surface of the patient's nasal cavity through a plurality of ports in the elongate tubular members. The delivery of the fluid causes cooling by direct heat transfer through the nasopharynx and hematogenous cooling through the carotids and the Circle of Willis.

The invention provides compositions comprising cyclodextrins encapsulating a selective ATP inhibitor, as well as uses thereof.

The invention provides compositions comprising cyclodextrins encapsulating a selective ATP inhibitor, as well as uses thereof.

The invention provides compositions comprising cyclodextrins encapsulating a selective ATP inhibitor, as well as uses thereof.

The field of the invention relates to processes for preparing Asparagopsis oil compositions, comprising extracting at least one bioactive from a biomass of Asparagopsis into an oil to form the compositions. These compositions are suitable for reducing total gas production and/or methane production in a ruminant or pseudo-ruminant animal.

The field of the invention relates to processes for preparing Asparagopsis oil compositions, comprising extracting at least one bioactive from a biomass of Asparagopsis into an oil to form the compositions. These compositions are suitable for reducing total gas production and/or methane production in a ruminant or pseudo-ruminant animal.